1-5 of 5
Nathalie Bardy-Bouxin, PhD
Close
Sort by
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 896.
https://doi.org/10.1182/blood.V130.Suppl_1.896.896
Published: 2017
Journal Articles

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Carla Mamolo, Arlene Reisman, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf
Journal: Blood
Blood (2017) 130 (Supplement 1): 2895.
https://doi.org/10.1182/blood.V130.Suppl_1.2895.2895
Published: 2017
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Andreas Hochhaus, Prof. Dr., Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1618.
https://doi.org/10.1182/blood.V130.Suppl_1.1618.1618
Published: 2017
Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Michael J. Mauro, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Roberto Uehara, Eric Leip, PhD, Liza DeAnnuntis, Nathalie Bardy-Bouxin, PhD, Andreas Hochhaus, MD, Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1620.
https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620
Published: 2017
Journal Articles

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Jorge E. Cortes, Tim H. Brümmendorf, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Sashi Nadanaciva, D Phil, Nathalie Bardy-Bouxin, PhD, Mark Shapiro, MD, Eric Leip, PhD, Jeffrey H. Lipton, MD PhD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2015) 126 (23): 4041.
https://doi.org/10.1182/blood.V126.23.4041.4041
Published: 2015